ERCC4 and melanoma: Enhanced melanoma cell sensitivity to cisplatin, inhibition of NER activity, and decreased level of ERCC1-XPF heterodimers in ovarian cancer cells were observed after E-X PPI2 or E-X AS7 usage [91].